Colloidal Synthesis and Characterization of Molybdenum Chalcogenide Quantum Dots Using a Two-Source Precursor Pathway for Photovoltaic Applications

The drawbacks of utilizing nonrenewable energy have quickened innovative work on practical sustainable power sources (photovoltaics) because of their provision of a better-preserved decent environment which is free from natural contamination and commotion. Herein, the synthesis, characterization, and application of Mo chalcogenide nanoparticles (NP) as alternative sources in the absorber layer of QDSSCs is discussed. The successful synthesis of the NP was confirmed as the results from the diffractive peaks obtained from XRD which were positive and agreed in comparison with the standard. The diffractive peaks were shown in the planes (100), (002), (100), and (105) for the MoS₂ nanoparticles; (002), (100), (103), and (110) for the MoSe₂ nanoparticles; and (0002), (0004), (103), as well as (0006) for the MoTe₂ nanoparticles. MoSe₂ presented the smallest size of the nanoparticles, followed by MoTe₂ and, lastly, by MoS₂. These results agreed with the results obtained using SEM analysis. For the optical properties of the nanoparticles, UV–Vis and PL were used. The shift of the peaks from the red shift (600 nm) to the blue shift (270–275 nm and 287–289 nm (UV–Vis)) confirmed that the nanoparticles were quantum-confined. The application of the MoX₂ NPs in QDSSCs was performed, with MoSe₂ presenting the greatest PCE of 7.86%, followed by MoTe₂ (6.93%) and, lastly, by MoS₂, with the PCE of 6.05%.     

Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment

The current COVID-19 pandemic has tested the resolve of the global community with more than 35 million infections worldwide and numbers increasing with no cure or vaccine available to date. Nanomedicines have an advantage of providing enhanced permeability and retention and have been extensively studied as targeted drug delivery strategies for the treatment of different disease. The role of monocytes, erythrocytes, thrombocytes, and macrophages in diseases, including infectious and inflammatory diseases, cancer, and atherosclerosis, are better understood and have resulted in improved strategies for targeting and in some instances mimicking these cell types to improve therapeutic outcomes. Consequently, these primary cell types can be exploited for the purposes of serving as a “Trojan horse” for targeted delivery to identified organs and sites of inflammation. State of the art and potential utilization of nanocarriers such as nanospheres/nanocapsules, nanocrystals, liposomes, solid lipid nanoparticles/nano-structured lipid carriers, dendrimers, and nanosponges for biomimicry and/or targeted delivery of bioactives to cells are reported herein and their potential use in the treatment of COVID-19 infections discussed. Physicochemical properties, viz., hydrophilicity, particle shape, surface charge, composition, concentration, the use of different target-specific ligands on the surface of carriers, and the impact on carrier efficacy and specificity are also discussed.